Plasma fibrinogen decrease by a lipid-lowering drug in healthy subjects

1992 ◽  
Vol 65 ◽  
pp. S174
Author(s):  
R. Paniccia ◽  
E. Chiarantini ◽  
M. Boddi ◽  
M. Filippini ◽  
M. Costanzo ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Plasma Fibrinogen ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug

Effect of Ciprofibrate on Platelet Aggregation and Fibrinolysis in Patients with Hypercholesterolaemia

1985 ◽  
Vol 54 (02) ◽  
pp. 442-444 ◽  
Author(s):  
Iain A Simpson ◽  
A Ross Lorimer ◽  
Isobel D Walker ◽  
John F Davidson
Keyword(s):  
Platelet Aggregation ◽  
High Risk ◽  
Patient Group ◽  
Fibrinolytic Activity ◽  
High Risk Patient ◽  
Plasma Fibrinogen ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Potential Benefits ◽  
Lowering Drug

SummaryThe fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients.We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.

Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

2020 ◽  
Vol 20 (28) ◽  
pp. 2634-2647
Author(s):  
Dong-Dong Li ◽  
Pan Yu ◽  
Wei Xiao ◽  
Zhen-Zhong Wang ◽  
Lin-Guo Zhao
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Physicochemical Properties ◽  
Isoquinoline Alkaloid ◽  
Hypolipidemic Activity ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lipid Lowering Agent ◽  
Lowering Drug ◽  
Hypolipidemic Drugs

: Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering mechanism of berberine and studies for improving its hypolipidemic activity have been reported, but for the most part, they have been either incomplete or not comprehensive. In addition, there have been a few specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties, the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some proposals are put forward.

A large remaining potential in lipid‐lowering drug treatment in the type 2 diabetes population – a Danish nationwide cohort study

2021 ◽  
Author(s):  
Hanan Amadid ◽  
Pernille F. Rønn ◽  
Maria BN. Dunbar ◽  
Jakob S. Knudsen ◽  
Bendix Carstensen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Drug Treatment ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug

scholarly journals Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study

2018 ◽  
Vol 11 (12) ◽  
pp. 779-788 ◽  
Author(s):  
Alison M. Mondul ◽  
Corinne E. Joshu ◽  
John R. Barber ◽  
Anna E. Prizment ◽  
Nrupen A. Bhavsar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Use ◽  
White Men ◽  
Lipid Lowering ◽  
Black And White ◽  
Lipid Lowering Drug ◽  
Lowering Drug ◽  
Fatal Prostate Cancer ◽  
Aric Study

Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response

2005 ◽  
Vol 150 (6) ◽  
pp. 1154-1162 ◽  
Author(s):  
Ana Cenarro ◽  
Marta Artieda ◽  
Carmen Gonzalvo ◽  
Erardo Meriño-Ibarra ◽  
Rosa Arístegui ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Drug Response ◽  
Hepatic Lipase ◽  
Plasma Lipid ◽  
Lipid Lowering ◽  
Lipase Gene ◽  
Lipid Lowering Drug ◽  
Lowering Drug ◽  
Hepatic Lipase Gene
Sign in / Sign up

Export Citation Format

Share Document